With biomedical research and pharmaceutical development happening all over the world, it is exciting to see companies now finding a new interest in Autism and ASD. Cellceutix recently indicated that they are in a position to move forward with Autism treatment research.
"These announcements indicate that Cellceutix is in a prime position in the development of treatments for autism spectrum disorder," said Leo Ehrlich, the Chief Financial Officer of Cellceutix. "We are developing a novel compound for a disorder which has few treatment options. In an area that people were once skeptical about pharmaceutical advancements being possible, it is encouraging to see other companies showing significant interest."
Read more about this on the MarketWatch.
Cellceutix acquired the rights to KM-391, its compound for the treatment of autism spectrum disorder, last year and has been diligently developing the compound since. Cellceutix has already completed an animal study that shows very encouraging results. Details of the data from the study are available at the Cellceutix website at www.cellceutix.com.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment